The titration schedule isn't bureaucratic box-checking. It's the single most important factor in whether you succeed on GLP-1 therapy. Here's why — and how to navigate it.
Why This Matters: The #1 reason people quit GLP-1 therapy early is side effects from going too fast. The #1 reason they don't get results is staying at too low a dose for too long. Titration is the art of navigating between those two failure modes. Understanding it gives you control over your own outcome.
Titration is the process of gradually increasing a medication dose over time to find the dose that is both effective and tolerable for your body. It's standard practice for many medications — antidepressants, blood pressure drugs, and seizure medications are all titrated. GLP-1 drugs are titrated because their mechanism of action (slowing gastric emptying, affecting gut motility) is dose-dependent and takes time to adapt to.
Think of it like adjusting to a new level of spice. If you've never eaten spicy food and you start with the hottest dish on the menu, you'll have a miserable experience and probably swear off spicy food forever. If you start mild and work up, your body adapts at each level and eventually you're enjoying things that would have floored you at the beginning. GLP-1 titration works the same way — your GI system adapts to each dose before you move to the next.
The FDA-approved titration schedule for subcutaneous semaglutide (Wegovy) — which most compounded semaglutide programs follow — increases the dose every 4 weeks:
| Phase | Weeks | Dose | What to Expect |
|---|---|---|---|
| 1 | 1–4 | 0.25 mg | Adaptation phase. Mild GI effects possible. Little appetite change yet. |
| 2 | 5–8 | 0.5 mg | First therapeutic dose. Appetite suppression begins. "Food noise" starts quieting. |
| 3 | 9–12 | 1.0 mg | Meaningful weight loss typically begins. Stronger satiety after meals. |
| 4 | 13–16 | 1.7 mg | Increased efficacy. Some providers skip this step; others use it as a bridge. |
| 5 | 17+ | 2.4 mg | Maximum approved dose. Highest efficacy — average ~15% weight loss in STEP 1 trial. |
Tirzepatide's titration is longer — 6 phases versus 5 for semaglutide — because its dual GLP-1/GIP mechanism tends to produce stronger initial GI effects for some patients. The payoff is greater average weight loss at the maximum dose.
| Phase | Weeks | Dose | Notes |
|---|---|---|---|
| 1 | 1–4 | 2.5 mg | Adaptation only. Not therapeutic. |
| 2 | 5–8 | 5 mg | First therapeutic dose. Appetite changes begin. |
| 3 | 9–12 | 7.5 mg | Weight loss accelerates. Many find a good balance here. |
| 4 | 13–16 | 10 mg | Upper mid-range. Strong efficacy, good tolerability for most. |
| 5 | 17–20 | 12.5 mg | Near-maximum. Final step before highest dose. |
| 6 | 21+ | 15 mg | Max approved dose. ~20.9% mean weight loss in SURMOUNT-1 trial at this dose. |
The best programs adjust your schedule based on your response, not a rigid template.
Some patients — especially those eager to see results quickly — push their provider to escalate the dose faster than standard, or simply take the next dose level without waiting the full four weeks. The result is almost always a wave of nausea, vomiting, and fatigue that makes them miserable, and in many cases leads them to quit entirely.
The 4-week waiting period between dose increases isn't arbitrary. It takes approximately 5 half-lives of a drug to reach steady state — for semaglutide with its ~1-week half-life, that's roughly 5 weeks. The 4-week schedule is slightly aggressive by strict pharmacokinetic standards, which is why side effects at dose transitions are so common even when following the standard schedule. Rushing further compounds this.
The opposite mistake is equally common: patients who experience even mild side effects at a dose increase become reluctant to progress further. They stay at 0.5mg of semaglutide indefinitely because it's comfortable, even when weight loss has plateaued and the therapeutic ceiling has been hit.
0.25mg and 0.5mg semaglutide are initiation doses — they are not designed as long-term therapeutic doses for weight management. The bulk of weight loss efficacy comes at higher doses. Staying low because it's comfortable is choosing side-effect avoidance over outcomes. The goal is to find the highest dose you can tolerate comfortably — not the lowest dose you can tolerate at all.
If you're struggling with nausea or GI discomfort during titration, these evidence-based strategies help most patients:
Helimeds offers ongoing physician support throughout your dosing journey — not just a prescription.
Get Started with Helimeds →All clinical claims sourced from peer-reviewed literature, FDA documents, or named clinical trials. No Fluff. Just Sources.
Titration support included